We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

A Targetable Vulnerability in Breast Cancer Cells

News   Mar 31, 2019 | Original story from University of Helsinki

 
A Targetable Vulnerability in Breast Cancer Cells

New study reveals that FGFR4 phosphorylates the essential proteins (MST1/2) of Hippo tumor suppressor pathway preventing their activation and induction of programmed cell death in breast cancer cells. Cell death program can be reactivated by blocking FGFR4 function with a specific inhibitor. These findings suggest new options for eradicating cancer cells with excessive FGFR4 expression. Credit: M Varjosalo & Lehti Group

 
 
Advertisement
 

RELATED ARTICLES

How the Loss of a Single Protein Leads to a Relentless Neuromuscular Disease

News

A new study has laid out the steps that connect the neuromuscular disorder spinal muscular atrophy (SMA) to the mutations in the gene SMN1 that cause the condition. The research may explain how the mutations affect motor neurons and points the way to a better understanding of SMA.

READ MORE

KRAS Inhibitor Sotorasib Achieves Durable Clinical Benefit in Early Trial

News

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefit.

READ MORE

Could Psoriatic Arthritis Be Activated by the Same Receptor in Different Patients?

News

A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers identified high levels of a specific receptor in immune cells, giving promising evidence of a single cause for the disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE